Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

NCT02303392 is registered in ClinicalTrials.gov with Jennifer Woyach as lead sponsor.

NCT NCT02303392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Lead sponsor
Jennifer Woyach
Phase
Phase 1
Overall status
Completed
Start date
June 9, 2015
Completion date
April 18, 2022
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prolymphocytic leukemia, recurrent adult diffuse large cell lymphoma, recurrent mantle cell lymphoma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia